Market Trends of RNA Analysis Industry
Reagents/Consumables Segment is Expected to Hold a Significant Share
The reagents and consumables are ready-to-use products to simplify RNA analysis procedures and research. During the forecast period, the increased prevalence of infectious diseases and oncological occurrences are also expected to boost the segment's growth. In addition, the demand for high-quality reagents is growing, as is the usage of media and reagents in transcriptome investigations. The biotechnological industry's increased R&D efforts, government spending on life science research, and the growing research being done with integrated omics studies are all contributing to the growth of the reagents/consumables segment's growth.
According to the February 2022 update by WHO, cancer is one of the main causes of mortality worldwide, and cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. As a result of the high burden of cancer and infectious diseases, there is a greater demand for diagnosis in medical specialties and diagnostic care centers, which is expected to drive segmental growth during the forecast period.
Furthermore, the launch of products by the market players has propelled the growth of the market segment. For instance, in March 2021, PCR Biosystems, the United Kingdom-based specialist in DNA and RNA analysis, launched a range of Iso Fast BST Polymerase reagents for rapid, robust, and sensitive RNA amplification. Thus, owing to such product approvals, the segment is anticipated to witness significant growth during the analysis period.
North America is Expected to Hold a Significant Share of the Market
North America is expected to hold a significant share of the RNA analysis market due to the increasing product approvals and increasing cancer cases and infectious diseases in this region. The market in the region is also boosted by rising demand for various assay technologies, quantification of multiplexed RNA, the increased need for genetic testing and personalized treatment, and an increase in genetic variation and genetic mutation occurrences.
Cancer is one of the most diagnosed genetic diseases that can be inherited or arise from certain environmental exposures. According to the American Cancer Society 2022 update, prostate cancer was the leading cause of cancer in males, while in females, it was breast cancer. In addition, as per the source above, by age group, people of age 65 years and more accounted for 1,117,640 cases of cancer, which was the highest among all other age groups. RNA sequencing has been utilized in many aspects of cancer research and therapy and provided an effective approach to detecting different types of cancers and other rare diseases. Thus, with the high burden of cancer and other diseases, the demand for RNA analysis technologies is growing, and it is propelling the growth of the market.
Furthermore, the commercial sector's continued investment in transcriptomics-related R&D is allowing regional market players to produce tailored medicines. The market in the region is growing due to advancements in sequencing technology, increased acceptance of NGS technology, and an increase in the number of partnerships and collaborations. For instance, in March 2022, Quantabio launched the sparQ RNA seq HMR kit. It is an ultra-fast RNA next-generation sequencing (NGS) library preparation tool with integrated ribosomal RNA (rRNA) and globin mRNA depletion.
Additionally, in June 2022, Fluent BioSciences launched two breakthrough products for three single-cell RNA analyses, namely PIPseq T2 and T20 v3.0 kits. These capture up to 2,000 and 20,000 single cells or nuclei per reaction, respectively. Thus, owing to the abovementioned factors, the market in the region is expected to show significant growth over the forecast period.
